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Sir,
This is in response to the letter from Maraqa and Lansdown.
Our recent study was an attempt to present pattern of relapse,
method of detection of that relapse and its impact on outcome in
greater detail than has previously been reported in the literature.
For ipsilateral breast relapse, those clinically detected have a
significantly poorer outcome than those detected by patients
themselves or by mammography. As we stated, there is no
difference in outcome between methods of detection for axillary
relapse or contralateral cancers. All sites of relapse were analysed
separately as we felt this highlighted the observation that more
axillary than breast relapses are detected by clinicians. We
mentioned that there should be more emphasis on educating
patients to perform axillary self-examination.
Maraqa and Lansdown state that we reported clinically detected
cancers do less well, although the relevant paragraph relates to
ipsilateral breast relapses. It is clear from our Results section that
this is not true for all sites of relapse. Where all relapses are
discussed, we stated ‘our data suggest that regular clinical
examination does not improve outcome’.
Figures 4 and 5 in our paper present data only on ipsilateral
breast relapses; contralateral and axillary data were not excluded.
As stated, when analysed separately, there was no difference
between the three methods of detection for either site of relapse. If
all sites of relapse are analysed together, as Maraqa and Lansdown
correctly point out, there is no difference between methods of
detection of relapse (Figure 1 below; log rank 2 d.f., P¼0.0971),
although this was not presented in our paper.
We feel that Maraqa and Lansdown are missing out the main
point of our paper. The question is not whether palpable relapse
does less well than mammographically detected relapse. An
analysis of all patients including those with axillary relapse reveals
that patients with palpable relapse do significantly less well than
those with mammographically detected relapse (Figure 2; log rank
1 d.f., P¼0.0325), as shown by others previously (Voogd, 1999).
The question is whether patients obtain any significant clinical
benefit from attending routine clinics for clinical examination. In
the past, studies have grouped all palpable relapses together or
have combined all recurrences detected as part of follow-up. What
1.0
0.9
0.8
0.7
0.6
Method of detection
Clinical
Censored
Mammographic
Symptomatic
Censored
Censored
0.5
S
u
r
v
i
v
a
l
0.4
0.3
0.2
0.1
0.0
0 100
Time (months)
200
Figure 1 Overall survival for all sites of relapse (ipsilateral breast, axillary
and contralateral breast) analysed by the method of detection.
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Figure 2 Overall survival for all sites of relapse (ipsilateral breast, axillary
and contralateral breast) separated into palpable (clinician or patient
detected) vs mammographically detected.
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to the detection of relapse, and what is the outcome of patients
with palpable cancers who do not notice them on their own (ie, all
patients with clinically diagnosed relapse).
In our study, very few relapses were detected clinically.
Ipsilateral breast relapses found on clinical examination did less
well. Clinical detection of contralateral breast relapse was very
rare, with 2 events from 1312 patients over 10 years. Clinically
detected axillary relapse was somewhat more common, 9 axillary
relapses detected by clinical examination in 1312 women over 10
years of follow-up.
Potentially treatable relapse occurs at a constant rate, possibly
for life. Clinical detection of such relapse is a rare event, at around
0.1–0.2% of women per year. Tremendous effort is currently
expended in follow-up clinics for a very small yield, despite no
benefit in outcome, and a poorer outcome in some types of relapse.
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